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Abstract 
The ratio of painless sleep was 80% in our study. 
26 (52%) of the patients showed no side effects, while 10 (20%) had nausea and 6 (12%) 
had constipation. 8 (16%) of the patients were found to have other side effects. The frequency of 
those side effects was nausea, constipation, dizziness, vomiting, respiratory failure and diarrhea 
respectively.[table 4] 
Hydromorphone hydrochloride helped to eliminate sleep disorder, shortness of breath and 
snoring and relatively improved amount of sleep and adequacy of sleep. It was found that 90% of 
our patients were able to fall asleep in 1-5 minutes; however 82% did not have enough amount of 
sleep. 78% of patients had no feeling of dizziness during the day; 82% did not have shortness of 
breath; 80% reported that they slept without pain, while 41% reported that they did not sleep at 
all. 
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1. Introduction 
Sleep is necessary for the continuance of psychophysiological health. Sleep deprivation is 
reported to reduce immune condition by decreasing secretion of cytokine. Antitumoral cell levels 
are affected by sleep. Abnormal sleep pattern affects cortisol levels, which affects number of 
function of natural killer cells. This much effect on the immune system can cause cancer 
progression in the organism, which already struggles with cancer cells.[1] 
While health providers around the world have more than eighty opioid options, 
unfortunately there is only a limited number of  opioids that can be used in pain treatment in 
Turkey. Hydromorphone is an opioid analgesic, which is 5 times stronger than morphine. It has 
oral, subcutaneous, rectal, intravenous(iv) and spinal preparations in other countries. However, only 
push-pull form osmotic-controlled release oral delivery system (Oros) was introduced in Turkey. It 
began to be used in moderate-severe cancer pain treatment. 
In this study, we evaluated hydromorphone hydrochloride, which is a recent opioid option 
in Turkey. We studied the effectiveness, tolerability and side effects of  the medication on patients’ 
cancer pain.  
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2. Purpose 
We aimed to analyze the effect of  hydromorphone hydrochloride on sleep quality and 
contribution to emotional well-being in addition to elimination of  pain in cancer patients; and to 
present its effects on feelings of  depression, worthlessness, indifference. Thus, we analyzed ratios 
of  improvement of  family relationships and performing daily life without help. 
 
3. Method and material 
 
Study design 
This is a descriptive study. 
 
3. 1. The place and time of the study 
The study was carried out in Konya province between the years of 2010-2012, in 
department of Algology. 
 
3. 2 Population and sampling 
Patients with chronic cancer pain for at least 6 months and those using hydromorphone 
hydrochloride due to malign cancer pain were included in the study. Charts of 50 patients who were 
diagnosed with various cancers constituted the sampling patients who applied to the algology 
policlinic used only the third strong opioid as the weakest opioid followed by the last strong opioid 
after the nonsteroid for the pain. Only 50 patients were using hydromorphone hydrochloride at the 
time of the study. Because patients using hydromorphone hydrochloride formed a rare group of 
patients who could reach this stage of life in the last stages of the cancer disease. 
 
3. 2. 1. Data collection 
3. 2. 1. 1. Data collection method 
3. 2. 1. 2. Charts of  50 patients who were diagnosed with various cancers constituted 
the sampling. 
3. 2. 1. 3. Data collection tools 
        3. 2. 1. 4. patient file and phone survey. 
        3. 2. 1. 5. Data collection time 
        2010-2012 years. 
 
3. 2. 2. Limitations of the study/sample selection criteria 
Patients with intolerable nausea, vomiting, pregnant women, patients with dysphagia, those 
who were diagnosed with colon cancer, patients who cannot use drugs due to allergy, patients with 
severe liver-kidney failure, severe neurologic disorder, with opioid-related hypotension, severe 
respiratory dysfunction, severe ventricular dysfunction, hypothyroidism, ureteral stricture and 
prostate hypertrophy were excluded from the study.  
 
3. 2. 3. The generalizability of the study 
Demographic characteristics, duration of  hydromorphone hydrochloride use and dose pain 
types, episodic pain, adjuvant treatments of  the patients were recorded by screening patient charts 
in 2010-2012 period. Whether the patients needed different medications despite the treatment was 
noted. Location of  pain (back, chest, neck, leg) was noted and neurologic component was analyzed. 
Reliability, side effects and severity of  side effects of  the medication were noted. The dose starting 
side effects and the response of  side effect to medical treatment were noted. Patients who 
withdrew from medication and number of  patients who could not tolerate side effects were 
recorded. The patients who were excluded from the study for any reason were recorded. 
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After the analysis of  the charts, control visits were performed by the author for patients 
with ongoing hydromorphone hydrochloride treatment and telephone visits for the patients with 
no control visits and no chart register. 
 
3. 2. 4. Research ethics 
Approval of  NecmettinErbakan University Meram Faculty of  Medicine Ethics 
Committee (2012-73 ) was taken for the study. 
 
3. 2. 5. Evaluation of data 
Statistical Package for Social Sciences (SPSS) Windows 16 software was used for statistical 
analysis of  data. Data was used as average, standard deviation and number. VAS (Kruskal Wallis 
analysis or variance), Brief  Pain Inventory and MOS sleep scale of  patients were evaluated. Chi-
square test was used for body pain localization, medication doses, medication use period, 
adjuvant use, side effects, reasons for withdrawal from medication and additional medications. 
p<0.05 level was considered as statistically significant. 
 
4. Results  
Of  a total of  50 patients who were included in the study, 33 were male, 17 were female. 
Mean age of  the patients was 60.82±11,401. Of  the patients, 15 (30.0%) had back pain, 12 (24%) 
had low back pain, 8 (16%) had leg pain, 7 (14%) had chest pain and 8 (16%) had head-neck, 
shoulder, heel and extensive body pain complaints. No statistically significant difference was 
observed between the genders in terms of  location of  pain (p>0.05) [Table . 1] 
Analysis of  duration of  medication use of  the patients after inclusion in the study 
revealed that 26 (52%) patients used hydromorphone hydrochloride for one month; 9 (18%) used 
for two months; 3 (6%) used for three months, 5(10%) used for four months, 1 (2%) used for 
five months and 2 (4%) patients used hydromorphone hydrochloride for six months. 4 (8%) 
patients used the medication for a period shorter than one month. There was a statistically 
significant difference between duration of  medication use and gender of  the patients 
(p<0.05).[table 3] This difference was believed to result from higher number of  male participants. 
Analysis of  the treatments of  the patients revealed that 22 (44%) of  the patients did not 
take adjuvant; 28 (56%) used adjuvant together with opioid treatment. As for the adjuvants, 14 
(28%) patients used gabapentin; 7 (14%) patients used pregabalin and 2 (4%) patients used 
amitriptyline. Some patients were observed to use two adjuvants in combination. Weak opioid 
(tramadol) was added to the treatment of  5 (10%) patients. 
VAS values (VAS I) before hydromorphone hydrochloride use of  patients with 
nociceptive, neuropathic and mixed pains were found to be 7.5±1.05, 7.5±0.70 and 7.5±0.96 
respectively; while VAS values (VAS 2) after hydromorphone hydrochloride use were 2.7±1.80, 
1.5±0.70 and 2.6±1.56 respectively. Although patients with neuropathic pain had lower VAS II 
mean scores, intergroup comparisons found no statistically significant difference due to non-
homogenous distribution of  number of  patients (VAS I=p>0.992, VAS II=p>0.613).[Table 2 ] 
31 (62%) patients who did not have episodic pain did not need additional treatment to 
opioid treatment, while 13 (26%) of  19 patients used tramadol, 6 (12%) used transmucosal 
fentanyl. 
Analysis of  quality of  life of  the patients after inclusion in the study revealed that 
emotional well-being of  26 (52%) patients improved; family relationships of  7 (14%) improved 
and 6 (12%) patients were observed to walk comfortably without pain, while 7 (14%) patients 
reported depression-indifference and 4 (8%) patients reported no change in their lives after 
taking the medication. 
Some of  the patients in patient group had certain diagnosis-related side effects prior to 
using the medication since our patient group consisted of  cancer patients. Of  the patients, 26 
(52%) had no side effects, while 10 (20%) had nausea, 6 (12%) had constipation and 8 (16%) had 
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other side effects. The most common side effects were nausea, constipation, dizziness, vomiting, 
respiratory failure and diarrhea respectively [Table 4]. Some patients were found to have more 
than one side effect. It was found that primary diagnosis for the patient with respiratory failure 
was lung cancer and that he/she was given iv morphine in addition to the recommended 
treatment. 
35 (70%) of  the patients continued the treatment without withdrawing from medication. 
Sleep levels of  the patients showed that 40 (80%) of  the patients reported that they could 
sleep painlessly; 10 (20%) reported that they could not sleep. As for sleep levels of  patients after 
hydromorphone hydrochloride treatment, 45 (90%) patients reported that they fell asleep in 1-5 
minutes, while 3 male patients described falling asleep as poor and 2 male patients described 
going to sleep as uneasy. When the patients were questioned about adequacy of  sleep after 
starting the medication, 41 (82%) reported that they were not getting enough sleep, 9 patients 
reported that they were getting enough sleep and that they could sleep for 7-8 hours a day. While 
39 (78%) patents did not have daytime dizziness, 43 (86%) patients reported snoring during sleep 
and 9 (18%) reported shortness of  breath. 
30 (60%) of  the patients who were included in the study were satisfied with reduced pain. 
[table 6] When the patients were requested to evaluate decrease of  pain in % when compared to 
initial pain, 18 (36.9%) patients reported that their pain decreased by 30%; 18 (36%) reported 
that their pain decreased by 50% and 14 (28%) patients reported that their pain decreased by 
70%. 
Decrease of  pain in patients was evaluated by Brief  Pain Inventory (BPI). 32 (64%) 
patients reported that pain elimination was good and that pain after the treatment was at 
minimum level. 
Evaluation of  effectiveness of  treatment after the treatment was described as very good 
by 18 patients . 
 
Table. 1.Thelocalization of  thecasespain in the body 
 
 
Painlocalization 
back Headandneck chest leg waist Should
er 
wide heel 
man(n) 11 4 2 5 8 1 1 1 
Woman 
(n) 
4 1 5 3 4 - - - 
Total 15 5 7 8 12 1 1 1 
 
 
Table 2.Accordingtogendervasvalues (mean±sd). 
gender(n) VAS 1 VAS 2 p 
man (33) 8,00±0,93 2,00±1,50 0,00* 
woman (17) 7,00 ±1,06 2,00± 1,88 0,00* 
Total 7,50±,97 2,00±1,63 0,00* 
 
 
Table. 3. Durationuse of  drug (month) 
gender (n) 
< 1 
n (%) 
1  
n (%) 
2  
n (%) 
3  
n (%) 
4  
n (%) 
5  
n (%) 
6  
n (%) 
man (33) 3(9,1) 17(51,5) 8(24,2) 3(9,1) 1(3,0) 1(3,0) 0 
woman (17) 1(5,9) 9(52,9) 1(5,9) 0 4(23,5) 0 2(11,8) 
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Table. 4 ınpatıentsseenadverseffectsuseof   Hydromorphonehydrochloridbeforeandafter 
 Adverseffect 
nausea 
(n) 
vomit 
(n) 
constipation 
(n) 
Dizziness 
(n) 
Failurerespitarion 
(n) 
diarrhea 
(n) 
Beforedrug 4 - 3 2 - - 
Afterdrug 6 1 (2) 3 3 1(2) 1 (2) 
 
 
5. Discussion 
Hydromorphone hydrochloride was observed to be effective in treatment of  chronic 
cancer pain. It was found to decrease cancer pain especially in breast cancer patients. Pain-related 
sleep disorders significantly improved. Emotional well-being increased, while depression, 
worthlessness and indifference decreased. The treatment was observed to contribute to quality of  
life like improved family relationships, ability to walk and perform daily tasks without help. 
Hydromorphone 3-glucoronoid metabolite of  hydromorphone hydrochloride   formed 
by hepatic glucuronidation is inactive. The fact that the metabolite does not interact with other 
medications in patients group who receive multiple medications can make it preferable in patients 
with potential organ dysfunction.[2 ] 
In this study, decrease of  pain after the treatment was 64% according to brief  pain 
inventory.  In 36% of  patients, 50% of  initial pain was eliminated. Side effects were not serious 
and response was taken to medication (p> 0.100). Our findings are consistent with those of  
Carla I et all.[6] 
Episodic pain is temporary exacerbation periods of  stabile pain treatment and can be 
triggered by movement and physical activity. It is treated by oral, nasal, transmucosal opioids. 
Portenoy et all., defined prevalence of  episodic pain between 19-95%.[2] 
Prevalence of  episodic pain was found to be 38% in our study and transmucosal fentanyl 
and tramadol were used for treatment. Low frequency of  episodic pain was lower when 
compared to some literature can be explained by the fact that it causes less fluctuation in valley-
peak levels of  the used hydromorphone hydrochloride.[3] 
In our study, number of  nausea, which was 4 before medication use, increased to 6; 
number of  dizziness, increased from 2 to 3; number of  constipation remained the same; 1 
diarrhea, 1 vomiting and 1 respiratory depression was observed.  [table 4] 
Warning the patients about potential nausea, vomiting and constipation prior to the 
treatment and providing early medication can be effective. We believe that cancer stages of  
patients affect incidence of  side effects. 
Analysis of  quality of  patients in 50 patients we screened in this study showed that the 
patients who previously could not use their arms, couldn’t even hold a glass, dress and walk 
without help and who couldn’t perform daily tasks due to pain were able to perform those tasks 
after the provision of  effective analgesia and that they felt happier. The ratio of  painless sleep 
was 80% in our study. 
26 (52%) of  the patients showed no side effects, while 10 (20%) had nausea and 6 (12%) 
had constipation. 8 (16%) of  the patients were found to have other side effects. The frequency of  
those side effects was nausea, constipation, dizziness, vomiting, respiratory failure and diarrhea 
respectively.[table 4] 
Constipation, nausea and vomiting, which are the most common side effects reported in 
clinical studies (n=647) can be managed by dose reduction, laxatives and effective use of  
antiemetics. 
A large number of  studies which evaluated health-related quality of  life with special scales 
have shown that effective pain control is concerned with increased quality of  life.  [4,5,6,7], 
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5. 1. Conclusions and recommendations 
5. 1. 1. Usability of study results 
Hydromorphone hydrochloride helped to eliminate sleep disorder, shortness of  breath 
and snoring and relatively improved amount of  sleep and adequacy of  sleep. It was found that 
90% of  our patients were able to fall asleep in 1-5 minutes; however 82% did not have enough 
amount of  sleep. 78% of  patients had no feeling of  dizziness during the day; 82% did not have 
shortness of  breath; 80% reported that they slept without pain, while 41% reported that they did 
not sleep at all. 
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